Buffett’s Berkshire Still Isn’t Buying. Here’s What It Sold.
By
Andrew Bary Updated Aug. 21, 2021
Illustration by Elias Stein
If you’ve been waiting for
Berkshire Hathaway to spend a decent chunk of its $144 billion in cash and equivalents on an acquisition, you’ll have to wait a little longer—maybe a lot longer. Not only did Berkshire fail to make a significant purchase in the second quarter, but CEO Warren Buffett and his investment lieutenants, Todd Combs and Ted Weschler, were net sellers of about $1 billion of stocks in the period, according to the company’s latest 10-Q filing.
Berkshire pared its stakes in three drug stocks—
AbbVie , Bristol-Myers Squibb, and
Merck —all acquired in 2020. The company also sold seven million
General Motors shares in the quarter, cutting its holding to 60 million shares, now worth $3.2 billion. Berkshire trimmed its
Chevron position slightly, and added to its stake in grocer
Kroger .
There were no changes in its two largest holdings. The company’s
Apple stake held steady at 887 million shares, now worth $134 billion, and
Bank of America stood at 1.01 billion shares, worth $41 billion. Berkshire’s total equity holdings topped $300 billion as of June 30.
As for its own shares, Berkshire was a buyer, scooping up about $6 billion of stock in each of the past two quarters, or about 1% of the shares outstanding in each period.
And it wasn’t the only buyer; both share classes are up about 25% this year, ahead of the S&P 500 index’s total return of about 20%.